PainChek Ltd (AU:PCK)
ASX:PCK
Want to see AU:PCK full AI Analyst Report?
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$29.26M
Enterprise ValueAU$24.48M
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring SaaS ModelPainChek’s software-based, subscription/usage licensing aligns revenue with number of sites, residents and users, creating recurring, contractable cash flows. This business model is scalable and sticky in institutional aged-care settings, supporting predictable revenue growth and higher lifetime value per customer.
Revenue And Margin ImprovementAccelerating top-line growth combined with rising gross margin indicates improving unit economics and operational leverage. Sustained revenue expansion plus margin recovery can allow PainChek to spread fixed costs, improve operating leverage and create a clearer path to break-even if maintained over the next several quarters.
No Debt On Balance SheetHaving no debt removes fixed interest burdens and lowers near-term solvency pressure, giving flexibility in capital structure choices. This permits management to prioritize growth investments or negotiate non-dilutive partnerships, and reduces downside risk from interest-rate driven cash outflows while fundraising options are considered.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow around -6.8M signals the business is not yet self-funding. Continued cash burn forces reliance on external financing, risks dilution or covenant pressure, and constrains the company’s ability to invest in sales, R&D or larger rollouts without securing new capital.
Negative Shareholder EquityNegative equity reflects cumulative losses that erode the company’s capital buffer and can limit strategic options. It may impair lender confidence and complicate corporate transactions, increasing the likelihood of equity raises or restructurings that could be dilutive and divert management focus from execution.
Deep UnprofitabilityVery large negative margins show the current cost base is mismatched to revenue scale. Unless revenue growth accelerates significantly or operating expenses are restructured, profitability remains distant. This structural margin gap increases execution risk and heightens the capital needed to reach sustainable earnings.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.13 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$29.26M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 83 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PCK Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-1009.84%
Trailing 12-Months
Asset Growth
7.04%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---